<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508869</url>
  </required_header>
  <id_info>
    <org_study_id>MG-DYS-ROS</org_study_id>
    <nct_id>NCT03508869</nct_id>
  </id_info>
  <brief_title>Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skin Laser &amp; Surgery Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Skin Laser &amp; Surgery Specialists</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of
      Rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the improvement of facial erythema and flushing while using Mirvaso® and Dysport®
      treatments based on the clinician's and patient's assessments using a verified 5-point
      grading scale
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor asked site to suspend study.
  </why_stopped>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Actual">September 20, 2017</completion_date>
  <primary_completion_date type="Actual">September 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessments for Erythema</measure>
    <time_frame>6 months</time_frame>
    <description>% of subjects who achieve a grade of 0 or 1 on the 5-point grading scale for Erythema 6 months post Dysport treatment Subject achieving a grade of 0 or 1 or ≥ 2 grade of improvement from baseline at 6 months for Erythema on the 5-point grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Assessments for Flushing</measure>
    <time_frame>6 months</time_frame>
    <description>% of subjects who achieve a grade of 0 or 1 on the 5-point grading scale for Flushing 6 months post Dysport treatment Subject achieving a grade of 0 or 1 or ≥ 2 grade of improvement from baseline at 6 months for Flushing on the 5-point grading scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Safety evaluations will be performed at all visits. Adverse events, local tolerability (dryness, pruritus burning/stinging) and a facial exam will be performed for all visits.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Erythema and Flushing Associated With Rosacea</condition>
  <arm_group>
    <arm_group_label>Mirvaso® (brimonidine) topical gel, 0.33%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysport®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysport® in conjunction with Mirvaso</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dysport® in conjunction with Mirvaso</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvaso® (brimonidine) topical gel, 0.33%</intervention_name>
    <description>Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.</description>
    <arm_group_label>Mirvaso® (brimonidine) topical gel, 0.33%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport®</intervention_name>
    <description>Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.</description>
    <arm_group_label>Dysport®</arm_group_label>
    <other_name>Dysport® (abobotulinumtoxinA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%</intervention_name>
    <description>Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%</description>
    <arm_group_label>Dysport® in conjunction with Mirvaso</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female

          2. 18 years of age or older

          3. Clinical diagnosis of rosacea

          4. Moderate to severe persistent facial erythema associated with rosacea at baseline, as
             determined by: a grade of greater than or equal to 3 on the 5 point grading scale1
             (Figure 1)

          5. No known medical conditions that may interfere with study participation

          6. Willingness to not use any products on their face for the duration of the study

          7. Read, understand, and sign informed consent forms

          8. Willingness to sign photography release form

          9. Willing and able to comply with all follow-up requirements

         10. Willingness to undergo treatment using Mirvaso® Gel and Dysport®

        Exclusion Criteria:

          1. Any significant skin disease at treatment area

          2. Any medical condition which could interfere with the treatment

          3. Inability or unwillingness to follow the treatment schedule

          4. Inability or unwillingness to sign the informed consent

          5. Pregnant or lactating

          6. Allergy to cow's milk protein

          7. Previous or current use of Mirvaso® Gel

          8. Known hypersensitivity to Dysport® , Mirvaso® Gel or any of their ingredients

          9. Previous Dysport® treatment 6 months prior to the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skin Laser &amp; Surgery Specialists</investigator_affiliation>
    <investigator_full_name>David J. Goldberg, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
    <mesh_term>Adrenergic alpha-Agonists</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Acetylcholine Release Inhibitors</mesh_term>
    <mesh_term>Neuromuscular Blocking Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

